Hypertension: an unstudied potential risk factor for adverse outcomes during continuous flow ventricular assist device support

Lauren T. Wasson, Melana Yuzefpolskaya, Michiyori Wakabayashi, Hiroo Takayama, Yoshifumi Naka, Nir Uriel, Ulrich P. Jorde, Ryan T. Demmer, Paolo C. Colombo

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


In end-stage heart failure, left ventricular assist devices (LVADs) represent an exciting new frontier in which post-device implantation survival approaches that of heart transplant. However, expansion of this technology is still limited by complications that impact morbidity and mortality. Thus, it is essential to identify and optimize modifiable predictors of poor outcomes. One such predictor may be hypertension (HTN). Not only may chronic HTN as a traditional cardiovascular risk factor be present during long-term LVAD support, but HTN may also contribute to device malfunction or device-associated complications. Although current guidelines identify blood pressure (BP) control as important to outpatient continuous flow (CF) LVAD management, there is no evidence base to support these guidelines. Indeed, our comprehensive literature search did not identify any studies that evaluated post-device implantation HTN as a potential predictor of adverse CF-LVAD outcomes. HTN among CF-LVAD patients is likely a relatively unstudied factor because of difficulties using standard noninvasive techniques to measure BP in the setting of reduced pulsatile flow. Fortunately, recent research has elucidated the meaning of Doppler BP measurements and validated a slow-cuff deflation system for BP measurements in the setting of CF-LVAD support. Therefore, CF-LVAD researchers and clinicians may (1) consider potential mechanisms relating HTN to poor outcomes, (2) realize that HTN management is a stated goal despite scarce evidence, and (3) utilize the new reliable and valid methods for outpatient BP measurement that make research and management possible. It is critical and now feasible that research on HTN in the CF-LVAD patient population move forward.

Original languageEnglish (US)
Pages (from-to)317-322
Number of pages6
JournalHeart Failure Reviews
Issue number3
StatePublished - May 1 2015

Bibliographical note

Funding Information:
Dr. Wasson would like to acknowledge the NIH T32 Training Grant HL007343. Dr. Paolo Colombo would like to acknowledge the A. L. Mailman Family Foundation White Plains for its research support. Dr. Ulrich Jorde would like to acknowledge the Schwartz Scholarship.

Publisher Copyright:
© 2014, Springer Science+Business Media New York.


  • Blood pressure
  • Hypertension
  • Left ventricular assist devices
  • Outcomes


Dive into the research topics of 'Hypertension: an unstudied potential risk factor for adverse outcomes during continuous flow ventricular assist device support'. Together they form a unique fingerprint.

Cite this